Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of 131I-L19SIP in a prostate cancer patient

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 1, 2014, Pages 35-43

  Locher, Ricarda ^a   Erba, Paola A ^b   Hirsch, Burkhard ^a   Bombardieri, Emilio ^c   Giovannoni, Leonardo ^d   Neri, Dario ^e   Dürkop, Horst ^f   Menssen, Hans D ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF PISA   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d Philogen SpA   (Italy)

^e ETH ZURICH   (Switzerland)

^f Pathodiagnostik Berlin   (Germany)

Author keywords

131I L19SIP dosimetry; ED B fibronectin; Pharmacodelivery; Prostate cancer; Prostatic hyperplasia; Vascular targeting

Indexed keywords

CD34 ANTIGEN; DOCETAXEL; ESTRAMUSTINE; FIBRONECTIN; FIBRONECTIN EDB; IODINE 131; MITOXANTRONE; RADRETUMAB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DENSITY; DOSIMETRY; DRUG BINDING; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG UPTAKE; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY; TUMOR DIFFERENTIATION; VASCULARIZATION; WHOLE BODY SCINTISCANNING;

EID: 84892641161     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1538-6     Document Type: Article

References (35)

1. Antonarakis ES, Carducci MA (2012) Targeting angiogenesis for the treatment of prostate cancer. Expert Opin Ther Targets 16:365-376
2. Bellmunt J, Attard G, Bahl A, et al. (2012) Advances in the management of high-risk localized and metastatic prostate cancer. BJU Int 109:8-13
3. Bombardieri E, Coliva A, Chiesa C, et al. (2007) Phase I study with antifibronectin I-131-L19SIP: first dosimetric and therapeutic results. J Nucl Med 48(suppl 2):398, abstract 1681
4. Castellani P, Borsi L, Carnemolla B, et al. (2002) Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol 161:1695-1700 (Pubitemid 35265528)
5. Chen S, Chakrabarti R, Keats EC, Chen M, Chakrabarti S, Khan ZA (2012) Regulation of vascular endothelial growth factor expression by extradomain B segment of fibronectin in endothelial cells. Invest Ophthalmol Vis Sci. doi: 101167/iovs12-9766
6. Cheng L, Montironi R, Bostwick DG, Lopez-Beltran A, Berney DM (2012) Staging of prostate cancer. Histopathology 60:87-117
7. Cohen MMJ (2007) Vascular update: morphogenesis, tumors, malformations, and molecular dimensions. Am J Med Genet 140A:2013-2038
8. Corcoran NM, Gleave ME (2012) Targeted therapy in prostate cancer. Histopathology 60:216-231
9. Cordell JL, Falini B, Erber WN, et al. (1984) Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32:219-224
10. Czabanka M, Parmaksiz G, Bayerl SH, et al. (2011) Microvascular biodistribution of L19-SIP in angiogenesis targeting strategies. Eur J Cancer 47:1276-1284
11. De Candida LM, Rogers RJ (1999) Characterization of the expression of the alternative splicing of the ED-A, ED-B, and V-regions of fibronectin mRNA in bovine ovarian follicles and corpora lutea. Reprod Fertil Dev 11:367-377
12. Dewhirst MW, Tso CY, Oliver R, Gustafson CS, Secomb TW, Gross JF (1989) Morphologic and hemodynamic comparison of tumor and healing normal tissue microvasculature. Int J Radiat Oncol Biol Phys 17:91-99 (Pubitemid 19173243)
13. Ebbinghaus C, Scheuermann J, Neri D, Elia G (2004) Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis. Curr Pharm Des 10:1537-1549 (Pubitemid 38559765)
14. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG (2000) Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implication for angiogenetic tumor therapies. Cancer Res 60:1388-1393 (Pubitemid 30152012)
15. Epstein JI (2010) An update of the Gleason grading system. J Urol 183:433-440
16. Epstein JI, Feng Z, Trock BJ, Pierorazio PM (2012) Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 61:1019-1021
17. 131I-L19SIP) in patients with relapsed Hodgkin lymphoma and other lymphoproliferative malignancies. J Nucl Med 53:922-927
18. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA (2009) Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Cancer Res 69:4708-4715
19. Heidenreich A, Aus G, Bolla M, et al. (2008) EAU guidelines on prostate cancer. Eur Urol 53:68-80 (Pubitemid 350166735)
20. Kaspar M, Zardi L, Neri D (2006) Fibronectin as target for tumor therapy. Int J Cancer 118:1331-1339
21. Kelly WK, Halabi S, Carducci M, et al. (2012) Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30:1534-1540
22. Kosmehl H, Berndt A, Strassburger S, et al. (1999) Distribution of laminin and fibronectin isoforms in oral mucosa and oral squamous cell carcinoma. Br J Cancer 81:1071-1079 (Pubitemid 29516154)
23. Kriegsmann J, Berndt A, Hansen T, et al. (2004) Expression of fibronectin splice variants and oncofetal glycosylated fibronectin in the synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Rheumatol Inter 24:25-33 (Pubitemid 38168110)
24. Kuban DA, Thames HD, Levy LB, et al. (2003) Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57:915-928 (Pubitemid 37324109)
25. Mariani G, Lasku A, Pau A, et al. (1997) A pilot pharmacokinetic and immunoscintigraphic study with the Technetium-99m-labeled monoclonal antibody BC-1 directed against oncofetal fibronectin in patients with brain tumors. Cancer 80:2484-2489 (Pubitemid 28009502)
26. Matter CM (2004) Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ Res 95:1225-1233 (Pubitemid 39648214)
27. Menrad A, Menssen HD (2005) ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin Ther Targets 9:491-500 (Pubitemid 40883149)
28. National Center for Health Statistics (2010) Estimated cancer deaths based on US Mortality Data, 1969 to 2007 and reported by the North American Association of Central Cancer Registries (NAACCR), Centers for Disease Control and Prevention
29. Neumann AC, Chou W, Welch-Reardon KM, et al. (2013) Analysis of stromal cell secretomes reveals a critical role for stromal cell-derived hepatocyte growth factor and fibronectin in angiogenesis. Arterioscler Thromb Vasc Biol 33:513-522
30. Roder MA, Berg KD, Gruschy L, Brasso K, Iversen P (2011) First danish single-institution experience with radical prostatectomy: biochemical outcome in 1200 consecutive patients. Prostate Cancer 2011:1-5
31. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ (2004) Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3.478 consecutive patients: long-term results. J Urol 172:910-914 (Pubitemid 39096421)
32. Santimaria M, Moscatelli G, Viale GL, et al. (2003) Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 9:571-579 (Pubitemid 36182586)
33. 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 113:2265-2274
34. Swindle P, Eastham JA, Ohori M, et al. (2008) Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimen. J Urol 179:S47-S51 (Pubitemid 351483915)
35. Tannock IF, Fizazi K, Ivanov S, et al. (2013) Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 14:760-768